Curium Pharma was last valued at $7B. It comes from the Growth Equity of Nov 2025. The company is private, so there is no listed share price.
1 valuation. The latest, $7B post-money, was set by the Growth Equity in Nov 2025.
A private valuation is the price agreed in one transaction. The Curium Pharma valuation of $7B is a private-market figure from the Growth Equity dated 20 Nov 2025 .
The valuation holds until the next priced round or secondary sale. A private company founded in 2000 with roughly 150 people has no daily price and no order book between rounds.
The last valuation is $7B.
Lead investors for each round are in the funding timeline.
The routes section explains what is realistically available for a company at this stage.
No. Curium Pharma is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
